Published in J Intern Med on March 01, 2008
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
The immune system in atherosclerosis. Nat Immunol (2011) 6.51
Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 5.28
Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol (2009) 2.64
Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci (2011) 2.60
High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol (2010) 2.23
ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest (2008) 2.16
Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci (2012) 1.71
Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol (2010) 1.69
Uremia alters HDL composition and function. J Am Soc Nephrol (2011) 1.55
High-density lipoprotein cholesterol in diabetes: is higher always better? J Clin Lipidol (2011) 1.50
Helical structure and stability in human apolipoprotein A-I by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci U S A (2009) 1.50
Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res (2013) 1.47
Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep (2010) 1.46
The diverse functions of oxysterol-binding proteins. Annu Rev Cell Dev Biol (2010) 1.43
Enhanced atheroprotection and lesion remodelling by targeting the foam cell and increasing plasma cholesterol acceptors. Cardiovasc Res (2015) 1.40
Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res (2013) 1.25
Cholesterol oxidation in the retina: implications of 7KCh formation in chronic inflammation and age-related macular degeneration. J Lipid Res (2010) 1.22
The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials (2011) 1.21
Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol (2009) 1.17
Conformational flexibility of the N-terminal domain of apolipoprotein a-I bound to spherical lipid particles. Biochemistry (2008) 1.14
MicroRNA modulation of cholesterol homeostasis. Arterioscler Thromb Vasc Biol (2011) 1.14
Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. CMAJ (2010) 1.12
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2008) 1.12
Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. Mol Pharmacol (2010) 1.12
Macrophage cholesteryl ester mobilization and atherosclerosis. Vascul Pharmacol (2009) 1.11
Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. Genes Nutr (2012) 1.09
HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J (2009) 1.08
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
The bladder tumor suppressor protein TERE1 (UBIAD1) modulates cell cholesterol: implications for tumor progression. DNA Cell Biol (2011) 1.07
Zymosan-mediated inflammation impairs in vivo reverse cholesterol transport. J Lipid Res (2011) 1.04
Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice. Circulation (2013) 1.01
Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. JACC Cardiovasc Imaging (2012) 1.00
Development of a cell-based, high-throughput screening assay for cholesterol efflux using a fluorescent mimic of cholesterol. Assay Drug Dev Technol (2010) 1.00
HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta (2010) 0.99
Quantum dot and Cy5.5 labeled nanoparticles to investigate lipoprotein biointeractions via Förster resonance energy transfer. Nano Lett (2010) 0.98
The role of HDL in innate immunity. J Lipid Res (2010) 0.98
Regulation of signal transduction by HDL. J Lipid Res (2013) 0.97
Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome. Hum Mol Genet (2008) 0.96
Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano (2013) 0.96
Influence of apolipoprotein (Apo) A-I structure on nascent high density lipoprotein (HDL) particle size distribution. J Biol Chem (2010) 0.95
On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis (2009) 0.95
The tumor suppressor TERE1 (UBIAD1) prenyltransferase regulates the elevated cholesterol phenotype in castration resistant prostate cancer by controlling a program of ligand dependent SXR target genes. Oncotarget (2013) 0.95
Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. J Lipid Res (2012) 0.95
Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children. Atherosclerosis (2013) 0.94
Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J Clin Lipidol (2010) 0.94
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94
Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport. Curr Atheroscler Rep (2011) 0.93
Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem (2010) 0.93
From blood to gut: direct secretion of cholesterol via transintestinal cholesterol efflux. World J Gastroenterol (2010) 0.93
Peroxisome proliferator-activated receptor-α activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Arterioscler Thromb Vasc Biol (2011) 0.92
Apolipoprotein D in lipid metabolism and its functional implication in atherosclerosis and aging. Aging (Albany NY) (2009) 0.92
TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2. J Lipid Res (2010) 0.91
Effects of the Iowa and Milano mutations on apolipoprotein A-I structure and dynamics determined by hydrogen exchange and mass spectrometry. Biochemistry (2012) 0.90
Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microb Cell Fact (2015) 0.90
Regulation of ABCA1 functions by signaling pathways. Biochim Biophys Acta (2011) 0.90
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin Pharmacokinet (2013) 0.89
The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol Med (2012) 0.89
Novel lipid droplet-associated serine hydrolase regulates macrophage cholesterol mobilization. Arterioscler Thromb Vasc Biol (2013) 0.89
Impact of self-association on function of apolipoprotein A-I. J Biol Chem (2011) 0.89
Obesity and weight loss result in increased adipose tissue ABCG1 expression in db/db mice. Biochim Biophys Acta (2011) 0.88
Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep (2014) 0.88
Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens (2015) 0.87
Enhanced hepatic apoA-I secretion and peripheral efflux of cholesterol and phospholipid in CD36 null mice. PLoS One (2010) 0.87
Analysis of inflammatory and lipid metabolic networks across RAW264.7 and thioglycolate-elicited macrophages. J Lipid Res (2013) 0.87
Scavenger receptor class B member 1 protein: hepatic regulation and its effects on lipids, reverse cholesterol transport, and atherosclerosis. Hepat Med (2011) 0.86
Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol (2011) 0.86
"Micromanaging" metabolic syndrome. Cell Cycle (2011) 0.86
Cholesterol metabolism and homeostasis in the brain. Protein Cell (2015) 0.86
Apolipoprotein A-I binding to anionic vesicles and lipopolysaccharides: role for lysine residues in antimicrobial properties. Biochim Biophys Acta (2013) 0.86
Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors. J Biol Chem (2011) 0.85
Discovery of new liver X receptor agonists by pharmacophore modeling and shape-based virtual screening. J Chem Inf Model (2014) 0.85
24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury. Brain Res (2010) 0.85
Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function. Obesity (Silver Spring) (2012) 0.85
Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion. J Immunol (2009) 0.85
Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1. J Clin Invest (2015) 0.83
Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation. J Biol Chem (2012) 0.83
Side-chain oxysterols: from cells to membranes to molecules. Biochim Biophys Acta (2011) 0.83
Myelin-derived lipids modulate macrophage activity by liver X receptor activation. PLoS One (2012) 0.83
Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome. Lipids Health Dis (2012) 0.83
HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis (2009) 0.83
Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCT. J Lipid Res (2014) 0.83
Discovery of tumor markers for gastric cancer by proteomics. PLoS One (2014) 0.82
Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects. Lipids (2010) 0.82
Cellular Interaction and Cytotoxicity of the Iowa Mutation of Apolipoprotein A-I (ApoA-IIowa) Amyloid Mediated by Sulfate Moieties of Heparan Sulfate. J Biol Chem (2015) 0.82
MCP-1 impacts RCT by repressing ABCA1, ABCG1, and SR-BI through PI3K/Akt posttranslational regulation in HepG2 cells. J Lipid Res (2013) 0.82
Insulin-Like Growth Factor-1 Receptor Deficiency in Macrophages Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Apolipoprotein E-Deficient Mice. Circulation (2016) 0.81
Protein kinase A modulates the activity of a major human isoform of ABCG1. J Lipid Res (2012) 0.81
The thienotriazolodiazepine Ro 11-1464 increases plasma apoA-I and promotes reverse cholesterol transport in human apoA-I transgenic mice. Br J Pharmacol (2011) 0.81
Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men. Steroids (2012) 0.80
Coexistence of High Fibrinogen and Low High-density Lipoprotein Cholesterol Levels Predicts Recurrent Cerebral Venous Thrombosis. Chin Med J (Engl) (2015) 0.79
Treating low high-density lipoprotein cholesterol: what is the evidence? Ther Adv Endocrinol Metab (2014) 0.79
In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. J Lipid Res (2013) 0.79
Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J Biol Chem (2015) 0.79
Walnut oil increases cholesterol efflux through inhibition of stearoyl CoA desaturase 1 in THP-1 macrophage-derived foam cells. Nutr Metab (Lond) (2011) 0.79
PPAR Medicines and Human Disease: The ABCs of It All. PPAR Res (2012) 0.79
RNA binding protein HuR regulates the expression of ABCA1. J Lipid Res (2014) 0.78
In Vivo Inflammation Does Not Impair ABCA1-Mediated Cholesterol Efflux Capacity of HDL. Cholesterol (2012) 0.78
Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk. J Clin Lipidol (2010) 0.77
Cholesterol Transporters ABCA1 and ABCG1 Gene Expression in Peripheral Blood Mononuclear Cells in Patients with Metabolic Syndrome. Cholesterol (2015) 0.77